|
|
|
|
6-Benzylamino 4-oxo-1,4-dihydro-1,8-naphthyridines and 4-oxo-1,4-dihydroquinolines as HIV integrase inhibitors.
Nagasawa JY, Song J, Chen H, Kim HW, Blazel J, Ouk S, Groschel B, Borges V, Ong V, Yeh LT, Girardet JL, Vernier JM, Raney AK, Pinkerton AB
Bioorg Med Chem Lett. 2011 Jan 15;21(2):760-3
Synthesis and SAR of 2-aryl-3-aminomethylquinolines as agonists of the bile acid receptor TGR5.
Herbert MR, Siegel DL, Staszewski L, Cayanan C, Banerjee U, Dhamija S, Anderson J, Fan A, Wang L, Rix P, Shiau AK, Rao TS, Noble SA, Heyman RA, Bischoff E, Guha M, Kabakibi A, Pinkerton AB
Bioorg Med Chem Lett. 2010 Oct 1;20(19):5718-21
Synthesis and SAR of thiophene containing kinesin spindle protein (KSP) inhibitors.
Pinkerton AB, Lee TT, Hoffman TZ, Wang Y, Kahraman M, Cook TG, Severance D, Gahman TC, Noble SA, Shiau AK, Davis RL
Bioorg Med Chem Lett. 2007 Jul 1;17(13):3562-9
Diaryl substituted pyrazoles as potent CCR2 receptor antagonists.
Pinkerton AB, Huang D, Cube RV, Hutchinson JH, Struthers M, Ayala JM, Vicario PP, Patel SR, Wisniewski T, DeMartino JA, Vernier JM
Bioorg Med Chem Lett. 2007 Feb 1;17(3):807-13
3-(2-Ethoxy-4-{4-[3-hydroxy-2-methyl-4-(3-methylbutanoyl)phenoxy]butoxy}phenyl)propanoic acid: a brain penetrant allosteric potentiator at the metabotropic glutamate receptor 2 (mGluR2).
Cube RV, Vernier JM, Hutchinson JH, Gardner MF, James JK, Rowe BA, Schaffhauser H, Daggett L, Pinkerton AB
Bioorg Med Chem Lett. 2005 May 2;15(9):2389-93
Allosteric potentiators of the metabotropic glutamate receptor 2 (mGlu2). Part 3: Identification and biological activity of indanone containing mGlu2 receptor potentiators.
Pinkerton AB, Cube RV, Hutchinson JH, James JK, Gardner MF, Rowe BA, Schaffhauser H, Rodriguez DE, Campbell UC, Daggett LP, Vernier JM
Bioorg Med Chem Lett. 2005 Mar 15;15(6):1565-71
Allosteric potentiators of the metabotropic glutamate receptor 2 (mGlu2). Part 1: Identification and synthesis of phenyl-tetrazolyl acetophenones.
Pinkerton AB, Cube RV, Hutchinson JH, Rowe BA, Schaffhauser H, Zhao X, Daggett LP, Vernier JM
Bioorg Med Chem Lett. 2004 Nov 1;14(21):5329-32
Phenyl-tetrazolyl acetophenones: discovery of positive allosteric potentiatiors for the metabotropic glutamate 2 receptor.
Pinkerton AB, Vernier JM, Schaffhauser H, Rowe BA, Campbell UC, Rodriguez DE, Lorrain DS, Baccei CS, Daggett LP, Bristow LJ
J Med Chem. 2004 Aug 26;47(18):4595-9
Pharmacological characterization and identification of amino acids involved in the positive modulation of metabotropic glutamate receptor subtype 2.
Schaffhauser H, Rowe BA, Morales S, Chavez-Noriega LE, Yin R, Jachec C, Rao SP, Bain G, Pinkerton AB, Vernier JM, Bristow LJ, Varney MA, Daggett LP
Mol Pharmacol. 2003 Oct;64(4):798-810
Group II mGlu receptor activation suppresses norepinephrine release in the ventral hippocampus and locomotor responses to acute ketamine challenge.
Lorrain DS, Schaffhauser H, Campbell UC, Baccei CS, Correa LD, Rowe B, Rodriguez DE, Anderson JJ, Varney MA, Pinkerton AB, Vernier JM, Bristow LJ
Neuropsychopharmacology. 2003 Sep;28(9):1622-32
View All Publications
Anthony Pinkerton's Research Focus
Dr. Pinkerton joined the Sanford-Burnham Medical Research Institute in February 2010 as Associate Director of Medicinal Chemistry at the Conrad Prebys Center for Chemical Genomics where he is a team leader for numerous probe and drug discovery efforts. Prior to that he was Associate Director of Medicinal Chemistry at Ardea Biosciences leading project teams in antiviral and anticancer drug discovery. Previously, he led medicinal chemistry teams at Kalypsys, Inc. and Merck Research Laboratories, and has experience with a broad range of target types and therapeutic areas including diabetes, oncology, inflammation and schizophrenia, and has been on or led teams that have advanced several compounds in to preclinical development. He received his Ph.D. in Chemistry from Stanford University and was a Fulbright Scholar at ETH-Zurich prior to graduate school. While at Stanford he developed new metal catalyzed reactions for synthesis and completed the total synthesis of several natural products.
About Anthony Pinkerton
Experience
Dr. Pinkerton earned his Ph.D. in chemistry from Stanford University in 2001. He was also a Fulbright Scholar at the Eidgenössische Technische Hochschule (ETH)- Zurich from 1995-1996.
|
|
|
|
|
|